Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 07, 2026 13:15 ET | Source: Ottimo Pharma Limited

Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody

First patient dosed and study open in leading oncology centers in US and AustraliaPhase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early...
January 07, 2026 12:03 ET | Source: AB Science

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN...
January 07, 2026 12:03 ET | Source: AB Science

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA...
January 07, 2026 09:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences
January 07, 2026 09:00 ET | Source: Genmab A/S

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

Media ReleaseCOPENHAGEN, Denmark; January 07, 2026 Supports Genmab’s ambition to build an AI-enabled innovation model that advances the company’s vision of bringing transformative antibody...
January 07, 2026 08:05 ET | Source: ARTIS Ventures

Luminate Raises $21 Million in Funding to Expand Home Cancer Treatment

GALWAY, IRELAND, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Luminate, a healthcare technology company which helps patients to receive cancer treatments at home, has raised $21 million in an expanded Series A...
January 07, 2026 08:00 ET | Source: Artios Pharma

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference

Artios Pharma to present at the 2026 J.P. Morgan Healthcare Conference, highlighting its ATR and Polθ inhibitor programs targeting DDR in cancer.
January 07, 2026 07:00 ET | Source: Avance Clinical

Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence

Avance Clinical Strengthens Global Oncology Offering with Acquisition of U.S.-Based LumaBridge and Establishes New Oncology Center of Excellence.
January 07, 2026 07:00 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients...